Adaptive Biotechnologies Inc., a biotech firm specializing in immune-driven therapies, reached a 52-week high of 28.87 USD on the trading day, following a robust year-over-year performance. The stock has climbed 117.55% over the past year and 71.74% year-to-date, despite a second-quarter adjusted loss of 25 cents per share—above the 14 cents per share analysts had anticipated. Revenue for the quarter hit 71.6 million USD, exceeding estimates of 65.8 million USD and marking a 22% increase from the prior-year period. Core minimal residual disease (MRD) business revenue grew 49% year-over-year, while overall revenue rose 50% from the same quarter last year.
Adaptive Biotechnologies stock reaches 28.87 USD, 52-week high
Revenue growth and analyst upgrades support a 117.5% year-over-year surge, though adjusted loss misses expectations.
PA
Priya Anand · Equities & Earnings Desk · 25 Sept 2026 · 01:54 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
